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Abstract 
Introduction: We explored the safety and efficacy of exenatide BID v. insulin glargine in a subgroup of Polish patients with type 2 diabetes 
sub-optimally controlled with metformin plus a sulfonylurea, participating in a 26-week randomised, controlled open-label trial. 
Material and methods: In Poland, 80 patients (HbA1c 7–10%, BMI 25–45 kg/m2) were randomised to exenatide 10 µg BID (n = 40) or in-
sulin glargine once daily (n = 40). We present exploratory analyses on HbA1c, glucose profiles, body weight, hypoglycaemia and adverse 
events (AEs).
Results: Mean (SD) baseline HbA1c was 7.9% (0.86) for exenatide and 7.8% (1.02) for insulin glargine. At Week 26, LS mean (SEM) HbA1c 
decreased in both groups (exenatide –0.72% [0.12]; glargine –0.64% [0.12]), as did fasting glucose. Postprandial glucose excursions after 
breakfast and dinner were smaller in patients treated with exenatide. LS mean (SEM) body weight decreased by –1.9 (0.48) kg with ex-
enatide and increased by 1.6 (0.48) kg with glargine (group difference [95%CI]: –3.5 kg [–4.9 to –2.2]). Hypoglycaemia was low in both 
groups; nocturnal hypoglycaemia was reported for three v. seven patients (three v. 24 episodes) in the exenatide and glargine groups, 
respectively. Adverse events were more common with exenatide (nausea n = 22 v. n = 1, vomiting n = 5 v. n = 0, headache n = 8 v. n = 2).
Conclusion: This exploratory analysis confirms that findings from the global study apply to patients treated with exenatide BID and 
glargine in Poland, showing that exenatide BID was as effective as insulin glargine. Data suggested that changes in HbA1c were similar, 
with fasting glucose changes greater in the glargine group and postprandial changes greater in the exenatide BID group. Exenatide BID 
was associated with weight reduction, less nocturnal hypoglycaemia, but more gastrointestinal events compared to glargine. 
(Endokrynol Pol 2013; 64 (5): 375–382)
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Streszczenie
Wstęp: Ocena bezpieczeństwa i efektów leczenia analogiem GLP-1 (eksenatyd) i długodziałajacym analogiem insuliny (glargina) pa-
cjentów z cukrzycą typu 2, nieskutecznie leczonych doustną terapia skojarzoną, biorących udział w polskiej grupie 26-tygodniowego, 
wieloośrodkowego, otwartego, randomizowanego badania klinicznego GWAA. 
Materiał i metody: 80 pacjentów z cukrzycą typu 2 skojarzoną z otyłością (BMI 25–45 kg/m2), nieskutecznie (7% < HbA1c < 10%) leczonych 
doustną terapią skojarzoną (metformina + pochodna sulfonylomocznika) zostało zrandomizowanych do dwóch grup leczenia interwen-
cyjnego. Pierwsza otrzymywała eksenatyd 20 µg/dobę, a druga glarginę w jednej dawce na dobę. Analizie porównawczej poddano masę 
ciała, BMI, HbA1c, dobowy profil glikemii i działania niepożądane. 
Wyniki: Średnie stężenie HbA1c było 7,9% (0,86) i 7,8% (1,02) w odpowiednich grupach, W 26 tygodniu leczenia uzyskano redukcję HbA1c 
w obu grupach (eksenatyd –0,72% [0,12]; glargina –0,64% [0,12]). Poposiłkowa glikemia, po śniadaniu i kolacji, była niższa u pacjentów 
leczonych eksenatydem. Masa ciała w tej grupie uległa redukcji 1,9 (0,48) kg, natomiast wzrosła 1,6 (0,48) kg u pacjentów leczonych insu-
liną (różnica: –3,5 kg [95%CI –4,9; –2,2]). Nocne hipoglikemie zostały zgłoszone przez 3 pacjentów w porównaniu do 7 (3 v. 24 epizody) 
odpowiednio w grupie leczonej eksenatydem i glarginą. Objawy uboczne występowały częściej w grupie leczonej eksenatydem (nudności 
n = 22 v. n = 1, wymioty n = 5 v. 0, bóle głowy n = 8 v. n = 2) w porównaniu z grupą leczoną glarginą.
Wnioski: Eksenatyd był równie efektywny jak glargina w zakresie wyrównania gospodarki węglowodanowej w badanych grupach 
pacjentów z cukrzycą typu 2. Terapia eksenatydem skuteczniej obniżała glikemie poposiłkowe, zaś insulinoterapia zapewniała niższe 
glikemie na czczo. Przewagą leczenia eksenatydem była redukcja masy ciała oraz mniej epizodów hipoglikemii, jednak przy większej 
częstości objawów ubocznych ze strony przewodu pokarmowego. (Endokrynol Pol 2013; 64 (5): 375–382)
Słowa kluczowe: cukrzyca typu 2, agonista GLP-1, eksenatyd, insulina glargina
This study was sponsored by Eli Lilly and Company and Amylin Pharmaceuticals LLC. 
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Introduction 
Type 2 diabetes mellitus (T2DM) is a chronic, progres-
sive disease, comprising one of the biggest unsolved 
problems of healthcare systems worldwide. Its pro-
gressive vascular complications, associated with an 
acceleration of atherosclerosis, are the main cause of 
the increased mortality of patients with T2DM [1–3]. 
Multifactorial therapeutic approaches play a vital role 
in preventing and blocking the macro- and microvas-
cular diabetic complications. A more individualised 
therapeutic approach is often needed, using drugs 
with different mechanisms of action depending on the 
individual stage of diabetes [4]. 
It has been suggested that incretin hormones 
are an essential component of normal glucose ho-
meostasis; they enhance glucose-dependent insulin 
secretion after meals [5, 6]. The incretins, of which 
glucagon-like-peptide-1 (GLP-1) and glucose-de-
pendent insulinotropic polypeptide (GIP) appear 
the most important in humans, are released from 
the intestines following food intake. The incretin 
effect describes the observation that oral glucose 
induces a greater insulin response compared to an 
equivalent intravenous challenge. The incretin re-
sponse accounts for approximately 70% of the total 
insulin secreted following the administration of oral 
glucose [7]. Their mechanism of action is to increase 
insulin secretion, decrease glucagon release, reduce 
food intake, and slow gastric emptying, which makes 
GLP-1 based therapies appropriate for treatment of 
T2DM. They have been associated with improvement 
in postprandial and, to a lesser extent, fasting glucose 
levels. In addition, they have been associated with 
weight loss and may help to preserve b-cell function, 
both major problems in T2DM patients [8–11]. The 
outcomes of initial clinical trials with GLP-1 analogues 
or GLP-1 receptor activation as well as with inhibitors 
of dipeptidyl peptidase-4, the enzyme responsible for 
proteolysis of incretins, in T2DM patients were very 
promising [12–14]. In recent years, incretin-based 
therapy has attracted interest as a novel therapeutic 
alternative for patients with T2DM [15, 16]. 
To date, no clinical data has been reported for 
exenatide twice daily (bis in die, BID) treatment in 
patients from Poland. Therefore, we explored the 
safety and efficacy of exenatide BID v. the long-
acting insulin analogue glargine in a cohort of 
Polish patients participating in the global clinical 
trial reported by Heine et al. [17]. This randomised, 
multicentre, controlled, open-label trial compared 
exenatide BID v. insulin glargine in patients with 
T2DM sub-optimally controlled with metformin 
and a sulfonylurea.
Material and methods
Data source and overall study protocol
Data from a 26-week, multicentre, comparator-con-
trolled, open-label, randomised, two-arm clinical trial 
was used for this analysis [17]. Following a four-week 
screening period, patients with T2DM sub-optimally 
controlled with metformin and a sulfonylurea were 
randomly assigned at baseline (1:1) to one of two in-
jectable medications: exenatide BID (initial dose 5 µg 
BID for four weeks, subsequently increased to 10 µg 
BID; subcutaneously injected 15 minutes before morn-
ing and evening meals); or insulin glargine (injected 
subcutaneously once daily at bedtime, initial dose 10 
IU per day). A fixed-dose algorithm was used to adjust 
the insulin glargine dose [17]. Patients self-titrated 
the dose in 2-IU increments every three days based 
on fasting blood glucose concentrations to achieve 
a target concentration of < 5.6 mmol/L (< 100 mg/ 
/dL). The study was conducted in accordance with the 
principles described in the Declaration of Helsinki. 
All study participants gave informed written consent 
before participation. The overall clinical study protocol 
was approved by the Ethics Committees within each 
country; for Poland, this was the Ethical Review Board 
of the Medical University of Lublin.
The primary objective of the overall study was to test 
the hypothesis that glycaemic control, as measured by 
change in HbA1c, achieved with exenatide BID is non-
inferior to that of insulin glargine. A further description 
of the study design has been published elsewhere [17]. 
Study population
For the overall trial, 551 patients had been randomised 
at 82 sites in 13 countries [17]. Of these, 80 patients, 40 
in each treatment group, had been enrolled in Poland 
between June 2003 and April 2004. Table I summarises 
the main inclusion and exclusion criteria.
Assessments 
HbA1c was measured at screening, randomisation (base-
line, week 0), and at Weeks 12 and 26. Blood chemistries 
were assessed at screening and at Weeks 12 and 26. A 
central laboratory performed all HbA1c measurements, 
fasting serum glucose (FSG), and other laboratory tests. 
Seven-point, self-monitored blood glucose (SMBG) 
profiles were performed at screening and at Weeks 4, 
8, 12, 18, and 26. Measurements were taken before the 
three main meals, two hours after the start of each meal, 
and during the night (3:00 a.m.). 
Adverse events (AEs) were assessed at each visit. 
Symptomatic hypoglycaemia was defined as a blood 
glucose measurement below 3.4 mmol/L (< 60 mg/dL) 
or hypoglycaemia accompanied by typical clinical symp-
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toms. Severe hypoglycaemia was defined as an episode 
with symptoms consistent with hypoglycaemia in which 
the patient required the assistance of another person and 
which was associated with either a blood glucose con-
centration < 2.8 mmol/L (50 mg/dL) or prompt recovery 
after oral carbohydrate, glucagon, or intravenous glucose.
Statistical analysis
All statistical analyses were done post-hoc on the 
subgroup of Polish patients who participated in the 
international clinical trial. Baseline characteristics, dose 
information, and AE data were analysed descriptively; 
means and standard deviations (SD) are presented 
for continuous variables. To explore the changes from 
baseline in HbA1c, an exploratory analysis of covariance 
(ANCOVA) model was performed, with treatment and 
baseline HbA1c as covariates, applying the last-obser-
vation-carried-forward (LOCF) approach. Results were 
presented as least-square (LS) means and standard error 
of the mean (SEM) for each group; and the correspond-
ing 95% confidence interval (CI) for the treatment group 
difference was reported. Similar exploratory models were 
calculated for other continuous variables including body 
weight and hypoglycaemia rate. Self-monitoring blood 
glucose profiles were explored with the same analytical 
approach used for HbA1c. To explore categorical data, 
Fisher ’s exact tests were calculated as appropriate. 
However, no confirmatory conclusions can be drawn. 
All results were presented for the intention-to-treat (ITT) 
population. The ITT population included all patients 
who took at least one dose of study drug and had at 
least one post-baseline measurement of the respective 
dependant variable. All calculations and analyses were 
performed using SAS software (SAS Institute, Inc., Cary, 
NC, USA).
Results
Patient characteristics
Of 551 patients randomised for the overall trial, 80 pa-
tients (14.5%, 40 per treatment group) had been enrolled 
in Poland and are reported here. Of these, 76 patients 
completed the study; three patients were withdrawn due 
to protocol violations (one patient in the exenatide BID 
group, two patients in the insulin glargine group), and one 
patient was withdrawn in the exenatide BID group based 
on patient decision. No patient discontinued due to AEs. 
Patient characteristics at baseline are presented in 
Table II; there were no notable differences between 
treatment groups. Patient age ranged between 41 and 
75 years, and 56% were female. 
In the Polish patient population, the mean final 
insulin glargine dose at week 26 was 16.6 U (median 
14, range 10–34 IU/day). Also the majority of exenatide 
patients in the Polish subset (n = 30 of 38 at Week 26) 
achieved the target dose of 20 µg/d.
Table I. Summary of main inclusion and exclusion criteria
Tabela I. Kryteria włączenia i wyłączenia
Inclusion criteria
Type 2 diabetes (WHO classification)
30–75 years of age, inclusive
Stable, optimal doses of metformin and SU for at least three months prior to screening
HbA1c ranging from 7.0% to 10.0% at the time of screening
Body mass index ranging from 25 kg/m2 to 45 kg/m2
A history of stable body weight (≤ 10% variation for ≥ 3 months before screening)
Exclusion criteria
Participation in an interventional medical, surgical, or pharmaceutical study within 30 days before screening
More than three episodes of severe hypoglycaemia within six months before screening
Therapy for a malignant disease other than basal-cell or squamous-cell skin cancer
Cardiac disease that was class III or IV according to the New York Heart Association criteria
Serum creatinine concentration > 135 µmol/L (> 1.5 mg/dL) for men or greater than 110 µmol/L (> 1.2 mg/dL) for women; or obvious clinical 
signs or symptoms of liver disease
Long-term (> 2 weeks) systemic glucocorticoid therapy or such therapy within two weeks immediately before screening
Using any prescription drug to promote weight loss within three months before screening
Treatment for > 2 consecutive weeks with insulin within three months before screening, with thiazolidinediones within four months before 
screening, with alpha-glucosidase inhibitors within three months before screening, or with meglitinides within three months before screening
SU — sulfonylurea; WHO — World Health Organisation
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Glycaemic control: HbA1c and FSG
Least-square mean HbA1c decreased from baseline to 
Week 26 in both treatment groups (Fig. 1). In the ex-
enatide BID group, LS mean (SEM) changes in HbA1c 
were –0.72% (0.12) at Week 26. In the insulin glargine 
group, the corresponding change was –0.64% (0.12). 
This translated into an estimated treatment group dif-
ference of -0.07% (LS mean group difference exenatide 
BID minus insulin glargine, based on exploratory AN-
COVA: –0.07% (0.17) [95% CI: – 0.41 to 0.26]). 
At Week 26, 42% of patients on exenatide and 38% 
of patients on insulin glargine had achieved the HbA1c 
target of ≤ 7%. Fasting serum glucose concentrations 
decreased in both treatment groups from baseline to 
Week 26. Least-square mean (SEM) FSG concentra-
tions decreased by -0.56  (0.40)  mmol/L in patients 
treated with exenatide BID and by –1.43 (0.39) mmol/L 
in patients treated with insulin glargine; starting from 
baseline concentrations of 9.67 (0.35) mmol/L and 
9.47 (0.35) mmol/L, respectively. For the change in FSG, 
the LS mean treatment group difference [95% CI] de-
rived from the exploratory ANCOVA model (exenatide 
minus insulin glargine) was 0.87 [–0.24 to 1.98] mmol/L.
Body weight
Patients on exenatide BID progressively lost body weight, 
while patients on insulin glargine gained weight (Fig. 2). 
Baseline mean (SD) body weights were 84.6 (15.86) kg 
and 86.7 (17.47) kg in the exenatide BID and the insulin 
glargine group, respectively. LS mean (SEM) weight 
decreased by –1.9 (0.48) kg on exenatide BID compared 
to a weight gain of 1.6 (0.48) kg on insulin glargine. At 
Week 26, the treatment group difference had reached 
–3.5 kg (LS mean group difference exenatide BID minus 
insulin glargine, based on exploratory ANCOVA: –3.5 
(0.68) kg [95% CI: –4.9 to –2.2 kg], p < 0.001). 
SMBG profiles
Average SMBG profiles at baseline and Week 26 are 
shown in Figure 3. In the exenatide BID group, the 
primary change was in postprandial glucose excursions, 
whereas in the insulin glargine group, the primary 
change was a reduction in fasting glucose concentra-
tions. In the exploratory ANCOVA analysis, LS mean 
(SEM) glucose excursions associated with exenatide BID 
decreased by 2.3 (0.28) mmol/L after breakfast and by 
1.6 (0.24) mmol/L after dinner, compared to 0.3 (0.29) 
Table II. Baseline characteristics of the study population
Tabela II. Charakterystyka badanej populacji
Characteristic Exenatide  
BID 
N = 40
Insulin  
glargine 
N = 40
Age (years) 60 ± 9 60 ± 9
Sex, female/male (n) 24/16 21/19
Weight [kg] 84.6 ± 15.86 86.7 ± 17.47
BMI [kg/m2] 32.0 ± 4.41 32.1 ± 5.23
Fasting serum glucose [mmol/L] 9.7 ± 0.35 9.5 ± 0.35
HbA1c (%) 7.9 ± 0.86 7.8 ± 1.02
Duration of diabetes (years) 9.15 ± 4.87 7.65 ± 5.41
Systolic blood pressure [mm Hg] 138 ± 14.2 143 ± 15.7
Diastolic blood pressure [mm Hg] 80 ± 7.2 84 ± 5.8
Data is for the intent-to-treat population. Values for continuous variables are 
expressed as means ± SD. BID — twice daily; BMI — body mass index; SD — 
standard deviation
Figure 1. (LS) Mean HbA1c (%) at each visit and at end-point, 
intent-to-treat population. Presented are mean and standard 
deviation for the values at each visit (0, 12, and 26 weeks); LS 
mean and standard error for the value at end-point (LOCF, from 
exploratory analysis of covariance analysis). BID — twice daily; 
LOCF — last observations carried forward; LS — least-square
Rycina 1. Zmiany HbA1C podczas poszczególnych wizyt w obu 
grupach badanych
Figure 2. LS mean change of body weight at each visit, intent-to-
treat population. Error bars indicate standard error of the mean. 
BID — twice daily; LS — least-square; wks — weeks
Rycina 2. Zmiany masy ciała podczas poszczególnych wizyt 
w obu grupach badanych
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mmol/L and 0.2 (0.24) mmol/L with insulin glargine 
(exploratory p < 0.001 for both meals). The responses 
after lunch in both treatment groups were similar.
Adverse events
Treatment-emergent AEs that occurred in ≥ 5% of 
patients are shown in Table III. Gastrointestinal events 
were more common in the exenatide BID group than 
in the insulin glargine group. No patients withdrew 
because of nausea or other gastrointestinal symptoms. 
All other AEs occurred only once.
Hypoglycaemia
Overall, 17 patients (42.5%) in the exenatide BID group 
and 14 patients (35.0%) in the insulin glargine group 
reported at least one hypoglycaemic episode. Hypogly-
caemia rates were low in both groups with 0.1 events/
patient/30 days (Table IV). Few patients in the exena-
tide BID group experienced nocturnal hypoglycaemic 
events — three patients reported one episode each, 
compared to seven patients reporting 24 episodes in the 
insulin glargine group, although this was not statisti-
cally significantly different. 
Discussion
A post-hoc pooled analysis found that both treat-
ments, patients treated with exenatide BID and starter 
insulins, experienced improvement in fasting glucose 
concentrations. Although changes in LS mean fasting 
glucose concentrations from baseline at 26 weeks in 
the insulin treatment group were statistically different 
from the exenatide BID treatment group in favour of the 
insulin group, these differences were not observed in 
the subgroup treated for one year. At 52 weeks, the LS 
mean fasting glucose concentrations were –1.9 mmol/L 
and -2.0 mmol/L for patients treated with insulin and 
exenatide BID, respectively [18].
Based on SMBG profiles, patients treated with 
exenatide BID had smaller postprandial glucose ex-
cursions, especially after morning and evening meals, 
Figure 3. Mean seven-point SMBG profiles at baseline and Week 26 in both treatment groups, intent-to-treat population. 
PP — postprandial; SMBG — self-monitoring blood glucose
Rycina 3. Siedmiopunktowy profil glikemii na początku badania i w 26. tygodniu, w grupach badanych
Table III. Adverse events reported in ≥ 5% of patients 
Tabela III. Zdarzenia niepożądane występujące u ≥ 5% 
pacjentów
Exenatide BID 
(N = 40)
Insulin glargine 
(N = 40)
Preferred term n (%) n events n (%) n events
Nausea 17 (43%) 22 1 (3%) 1
Headache 4 (10%) 8 2 (5%) 2
Vomiting 4 (10%) 5 0 (0%) 0
Nasopharyngitis 4 (10%) 4 2 (5%) 2
Upper abdominal pain 3 (8%) 3 0 (0%) 0
Hypertension 2 (5%) 2 0 (0%) 0
Respiratory tract 
infection 
2 (5%) 2 0 (0%) 0
BID — twice daily
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Table IV. Hypoglycaemia rates (events/patient/30 days)
Tabela IV. Częstość występowania hipoglikemii (epizod 
hipoglikemii/pacjent/30 dni)
Exenatide BID 
(N = 40)
Insulin glargine 
(N = 40)
Group 
difference 
(exenatide 
minus insulin 
glargine)
Hypoglycaemia LS mean SEM LS 
mean
SEM [95% CI] 
p-value
Overall 0.11 0.08 0.10 0.08 [–0.22; 0.22],  
p = 0.995
Nocturnal 0.00 0.05 0.10 0.05 [–0.25; 0.05],  
p = 0.175
CI — confidence interval; LS — Least-square, SEM — standard error of the mean
whereas insulin glargine appeared to predominantly 
affect fasting glucose concentrations. This pattern is 
consistent with the timing of dosing and exenatide’s 
mode of action. 
According to an analysis of epidemiological stud-
ies by Ceriello et al., postprandial hyperglycaemia is 
associated with a higher risk of cardiovascular disease 
and an increase in overall mortality [19]. Glucagon-
like-peptide-1 receptor agonists and other therapies 
shown to be effective in reducing postprandial glucose 
excursions may therefore potentially improve this car-
diovascular risk factor [17, 19-24].
One of the main factors that differentiates exena-
tide BID from insulin — reduction in body weight 
— was also observed in this country-specific patient 
cohort from Poland; mean weight decreased by –1.9 
kg in the exenatide BID group and increased by 1.6 kg 
in the insulin glargine group. Weight control is one 
of the important considerations in the treatment of 
patients with T2DM, according to the American Dia-
betes Association and the Polish Diabetes Association 
[24, 25]. Overweight and obesity are independent 
cardiovascular risk factors, and body weight reduction 
should be an integral component of treatment [26, 27]. 
The majority of oral glucose-lowering drugs used in 
T2DM, as well as insulin, result in weight gain or are 
at most weight-neutral [28]. Glucagon-like-peptide-1 
receptor agonists have consistently been demonstrated 
to have unique effects on reducing body weight [20, 
27–30]. In the UK Prospective Diabetes Study, the 
significant advantage of metformin over other oral 
antidiabetes medications in overweight and obese 
patients has been clearly shown [31]. Exenatide has 
been shown to reduce body weight in animals as well 
as in humans [32–35]. Exenatide reduced food intake 
in rodents following either central or peripheral ad-
ministration. Exenatide has been shown to inhibit the 
kinetics and secretory functions of the gastrointestinal 
tract, especially gastric emptying, which may result in 
a reduction of caloric intake and a progressive body 
weight reduction in rodents [34, 35] and humans [36]. 
This potential anorectic effect of exenatide and GLP-1 
is assumed to be caused by an activation of peripheral 
visceral nerve fibre endings located in the stomach 
wall, regulating the rate of stomach emptying [37, 
38]. But in addition, GLP-1 also acts centrally on the 
hypothalamic satiety centre, particularly on neurons 
of the arcuate nucleus in rats [39]. Currently, there 
is disagreement as to whether the central effect is 
or is not independent of the activation of peripheral 
visceral nerve fibres’ endings in the stomach wall [38, 
40]. Consistent with the weight reduction observed 
in animal studies, exenatide BID treatment among 
patients with T2DM has been associated with a delay 
in gastric emptying [40]. 
Use of exenatide BID may be more convenient for 
patients than treatment with insulin which requires 
more attention and trained personnel [41]. The diffi-
culty of monitoring and changing the doses of insulin 
is eliminated with the use of exenatide BID which 
does not require dose titration beyond the first month 
of treatment and the need for routine SMBG surveil-
lance is reduced in those patients who do not receive 
concomitant sulfonylurea [42].
Hypoglycaemia is a common and typical AE of 
drugs stimulating insulin secretion, such as sulfonylu-
reas. The incidence of hypoglycaemic events increases 
according to the intensity of therapy administered 
to achieve adequate glycaemic control [43]. In this 
Polish cohort, hypoglycaemia rates were low (0.1 
events/patient/30 days) in both groups; nocturnal 
hypoglycaemia was reported for three patients on 
exenatide BID v. seven patients on insulin glargine 
(three v. 24 episodes). In previous studies, hypogly-
caemic episodes (usually mild) were noted primar-
ily when exenatide was given in combination with 
a sulfonylurea, whereas they were less common 
when exenatide was combined with metformin [44]. 
This finding may be connected to the mode of action 
of these drugs. The potential insulinotropic effect of 
exenatide is glucose-dependent [45]. In contrast, sul-
fonylureas increase insulin secretion independently of 
glucose concentration, thereby resulting in a higher 
potential incidence of hypoglycaemia [44]. The pos-
sible interaction between molecular actions of GLP-1 
and glucose-lowering drugs such as sulfonylureas 
should be emphasised. Sulfonylureas can reduce the 
interaction between GLP-1 and glucose concentration, 
mainly by blocking of the K channel of adenosine 
triphosphate in b-cells, resulting in a persistent stimu-
lation of insulin secretion [45–47]. 
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The data is not entirely up-to-date (2004/2005) and 
these factors are potential limitations. The low patient 
number precludes any confirmatory conclusions.
Conclusions
This exploratory subgroup analysis confirms that find-
ings from the global study apply to patients treated 
with exenatide BID and glargine in Poland, showing 
that exenatide BID was as effective as insulin glargine. 
For this cohort of patients with T2DM inadequately 
controlled by metformin and sulfonylurea combina-
tion treatment, the data suggests that the changes in 
HbA1c were certainly similar, but decreases in fasting 
glucose were greater in the insulin glargine group and 
postprandial excursions were fewer in patients treated 
with exenatide BID. As previously seen in several large 
international trials, exenatide BID was associated with 
body weight reduction, a low incidence of nocturnal 
hypoglycaemia, but frequent occurrence of mild to 
moderate gastrointestinal events.
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